Sandbox Reserved 1108: Difference between revisions

Line 2:

==4iv6==

~~This~~ is ~~a default text for your page ''~~''''. ~~Click above on '''edit this page''' to modify~~. ~~Be careful with the < and > signs~~.

4iv6 is an enzyme ''Mycobacterium tuberculosis'' which get his structure analyzed by Baugh et al. [https://www.ncbi.nlm.nih.gov/pubmed/25613812] with other enzymes homologue in order to fight ''Mycobacterium tuberculosis'' relative infections.

~~You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10~~.~~1002/ijch~~.~~201300024<~~/~~ref> or to the article describing Jmol <ref>PMID:21638687<~~/~~ref>~~ to ~~the rescue~~.

== Function ==

Line 36:

Line 35:

[[Other information]]:

The enzyme from beef liver can accept acyl-chain lengths from 3 to 8 carbon atoms. From different organism the range can vary so we ignore if M.tuberculosis gets the same lengths resolution.

The enzyme from beef liver can accept acyl-chain lengths from 3 to 8 carbon atoms. From different organism the range can vary so we ignore if ''Mycobacterium tuberculosis'' gets the same lengths resolution.

The highest activity reported for beef liver enzyme was for substrates with 4 and 5 carbon acyl-chain lengths.

Line 44:

Line 43:

4iv6 which belong to ''Mycobacterium tuberculosis'' was studied with other protein homolog.

They were chosen to be studied as potential TB-Drugs target

Studies have been made on homolog similarities aimed on their active site because with the knowledges of many homolog active site structure and how they work, we can design a inhibitor of those enzyme which can stop essential reaction and reduce or stop ''M.tuberculosis'' infection.

Studies have been made on homolog similarities aimed on their active site because with the knowledges of many homolog active site structure and how they work, we can design a inhibitor of those enzyme which can stop essential reaction and reduce or stop ''Mycobacterium tuberculosis'' infection.

This strategy is called an « Homolog-rescue strategy ».

This strategy can be generalized for other drug target for other diseases.

Sandbox Reserved 1108: Difference between revisions

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 2: / Line 2: @@
 ==4iv6==
 <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
-This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
+iv6 is an  enzyme ''Mycobacterium tuberculosis'' which get his structure analyzed by Baugh et al. [https://www.ncbi.nlm.nih.gov/pubmed/25613812] with other enzymes homologue in order to fight ''Mycobacterium tuberculosis'' relative infections.
-You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
 == Function ==
@@ Line 36: / Line 35: @@
 [[Other information]]:
-The enzyme from beef liver can accept acyl-chain lengths from 3 to 8 carbon atoms. From different organism the range can vary so we ignore if M.tuberculosis gets the same lengths resolution.
+The enzyme from beef liver can accept acyl-chain lengths from 3 to 8 carbon atoms. From different organism the range can vary so we ignore if ''Mycobacterium tuberculosis'' gets the same lengths resolution.
 The highest activity reported for beef liver enzyme was for substrates with 4 and 5 carbon acyl-chain lengths.
@@ Line 44: / Line 43: @@
 iv6 which belong to ''Mycobacterium tuberculosis'' was studied with other protein homolog.
 They were chosen to be studied as potential TB-Drugs target
-Studies have been made on homolog similarities aimed on their active site because with the knowledges of many homolog active site structure and how they work, we can design a inhibitor of those enzyme which can stop essential reaction and reduce or stop ''M.tuberculosis'' infection.
+Studies have been made on homolog similarities aimed on their active site because with the knowledges of many homolog active site structure and how they work, we can design a inhibitor of those enzyme which can stop essential reaction and reduce or stop ''Mycobacterium tuberculosis'' infection.
 This strategy is called an « Homolog-rescue strategy ».
 This strategy can be generalized for other drug target for other diseases.